

Supplementary file 1: Supplementary Methods

Belonging to the manuscript:

Cost-effectiveness of paediatric influenza vaccination in the Netherlands

Pieter T. de Boer^{1,*}, Franklin C.K. Dolk^{1*}, Lisa Nagy^{2,*}, Jan C. Wilschut³, Richard Pitman², Maarten J. Postma^{1,3,4}

¹ Unit of Pharmacotherapy, -Epidemiology & -Economics (PTE2), Department of Pharmacy, University of Groningen, Groningen, the Netherlands

² ICON Health Economics and Epidemiology, Oxfordshire, United Kingdom

³ Department of Health Sciences, University Medical Center Groningen, Groningen, the Netherlands

⁴ Department of Economics, Econometrics & Finance, Faculty of Economics & Business, University of Groningen, Groningen, the Netherlands

*: These three authors have contributed equally to this manuscript

1. Transmission model (deterministic)

1.1. Transmission model data sources

Data were obtained from the following sources.

From Statistics Netherlands (CBS):

- Population and birth data ^{1,2}
- Life tables and mortality data ³

From the World Health Organization (WHO)

- Vaccine composition from 2010/2011 to 2013/14 ⁴
- Flunet influenza surveillance reports ⁵

From the National Institute for Public Health and the Environment (RIVM)

- Vaccination uptake rates from 2010/2011 to 2013/14 ⁶
- Recommendations ⁷

From the literature:

- Netherlands-specific age stratified contact (WAIFW) matrix ⁸
- Transmission model parameter estimates ^{9,10}
- Live attenuated and inactivated vaccine efficacy estimates ¹¹

1.2. Demographics

The model used a realistic age structure, stratified by age in months. The original model population used Dutch population data ¹ by single year of age for 2010, separated into monthly age bands by fitting a cubic spline to the cumulative population size by age. Aging was simulated on a monthly basis, with an upper age limit in the model of 100 years. Net immigration into the Dutch population was not modelled.

A birth rate of 15,366.4 live births per month was used, calculated as the average monthly birth rate over 2010 ².

A background mortality was applied by converting annual lifetable surviving proportions ³ by year of age to a daily mortality probability using: $P(\text{die})_{\text{day}} = 1 - P(\text{survive})_{\text{year}}^{(1/365)}$. As these values were very small the daily probabilities for each year of age were used as daily rates in the transmission model.

1.3. R_0

The basic reproductive number (R_0) is defined as the number of secondary infections arising from one average primary infection in a totally susceptible population^{12,13}. Using data from past pandemics, R_0 for influenza has been estimated to range from 1.6 to 3.9¹⁰.

1.4. Transmission model compartmental structure and equations

SEIRRS(V) structure

Each age band in the model was divided into compartments based on the natural history of infection and immunity status. For each virus the possible immunity statuses were: susceptible, exposed and latently infected, infectious, recovered (with initial immunity or with long-term immunity), and vaccinated (Table S1.1).

Table S1.1: Abbreviations for compartment status with respect to a single influenza strain.

Status	Abbreviation
Susceptible	S
Exposed (latently infected)	E
Infectious	I
Recovered (first immunity stage)	R _F
Recovered (long-term immunity)	R _L
Vaccinated	V

For a given influenza strain patients began as susceptible, moved to the exposed class upon infection and then the infectious class, before recovering with immunity that gradually waned until they were susceptible again. A proportion p of those who first gained naturally-acquired immunity to the strain would go on to develop long-term immunity, for which the duration was much longer than the first immunity stage. The other $1-p$ proportion of those leaving the first immunity stage lost their immunity altogether and returned to the susceptible class. Alternatively susceptible individuals could be vaccinated, for which the immunity also waned until they were again susceptible. The structure is therefore called SEIRRS(V) for brevity.

A diagram of the model structure for a single virus is presented in Figure S1.1. The subscript 'F' denotes the first recovered class and the subscript 'L' describes the recovered class for individuals who develop long-term immunity. The flow parameters are explained in Table S1.2.




Figure S1.1: Conceptual transmission model structure for a single virus. This diagram does not represent the full model, in which two influenza strains were modelled simultaneously. Flow parameters are explained in Table S1.2.

Table S1.2: Transmission model flow parameters

Parameter	Description
λ	Force of infection on susceptible individual (Equation 2)
γ	Rate of acquiring infectiousness given exposure (infection): reciprocal of average latent period
r	Rate of recovery: reciprocal of average infectious period
δ_F	Rate of waning of the First stage of naturally-acquired immunity
δ_L	Rate of waning of the Long-term naturally-acquired immunity
p	Probability of developing long-term natural immunity
μ	Mortality rate (natural)

In the transmission model two influenza strains were modelled simultaneously. Figure S1.1 is not the full model structure: it is meant only as a conceptual diagram of the stages for a single virus, with the other virus held constant.

Two-strain model

Influenza A and influenza B were simulated independently. Within an influenza type two strains were assumed to be modelled: a strain from each of the A (H1N1) and A (H3N2) subtypes for influenza A, and a strain from each of the B (Victoria) and B (Yamagata) lineages for influenza B. Both strains were modelled simultaneously so the model compartmental structure combined the SEIRRS(V) structure of each.

The combined SEIRRS(V) structure, except for vaccination, is shown in Figure S1.2. Model flows due to mortality are also left out of the diagram for simplicity. Of the two non-subscript letters in the compartment names, the left letter represents the status with respect to the first virus as in Table S1.1, and the right letter with respect to the second.

It can be seen that each horizontal (or vertical) line of compartments in the model corresponds to movement in the first (or second) virus only, as in Figure S1.1, with individuals maintaining the same immunity status for the second (or first) virus.

Compartments in which individuals are exposed or infectious with either virus are shaded to highlight the fact that the only flows out of these compartments are due to a change of status in the infected virus; patients cannot also change their status with respect to the other virus while in these compartments, i.e., they cannot be infected with both viruses at once.




Figure S1.2: Combined two-strain model structure, neglecting vaccinated classes. Model flow parameters and details of model flows due to mortality are left out for simplicity as they are detailed in Figure S1.1. Note that movement along a horizontal or vertical axis only equates to the single-virus compartment structure of Figure S1.1.

The combined SEIRRS(V) structure, including vaccination, is shown in Figure S1.3. Model flows due to mortality are left out of the diagram for simplicity, as are the flows between unvaccinated compartments which were detailed in Figure S1.2. Overall there were 32 states in the model structure.




Figure S1.3: Combined model structure including vaccination. Details of model flows between compartments with no vaccinated individuals are left out for simplicity as they are detailed in Figure S1.2.

Model equations

The model equations are an adaptation of a previously-published model to allow for two virus strains circulating simultaneously. Additionally, these equations were updated to stratify age by month of age, not year.

The flows of individuals between compartments are described by the following set (Equation 1) of linked differential equations for $m = 0, 1, 2, \dots, 1199$ months of age. The choice of compartment naming based on two letters, while it conceptually streamlines the flow diagram (Figure S1.3), becomes somewhat cumbersome for the differential equations (Equation 1) as it appears there are compartment populations being multiplied. With the exception of the transmission terms, in which the λ_i factor is dependent on the population infectious with strain i , there is no such multiplication. Each term in square brackets ('[]') is a single compartment population.

$$\begin{aligned}
\frac{d}{dt}\{ S S \} &= -\lambda_1[SS] + (1-p)\delta_{F1}[RFS] + \delta_{L1}[RLS] - F_{V1}[SS] + \nu_1[VS] \\
&\quad -\lambda_2[SS] + (1-p)\delta_{F2}[SRF] + \delta_{L2}[SRL] - F_{V2}[SS] + \nu_2[SV] - \mu[SS] \\
\frac{d}{dt}\{ E S \} &= \lambda_1[ES] - \gamma_1[ES] - \mu[ES] \\
\frac{d}{dt}\{ I S \} &= \gamma_1[ES] - r_1[IS] - \mu[IS] - \mu_F[IS] \\
\frac{d}{dt}\{ R_F S \} &= r_1[IS] - \delta_{F1}[RFS] - \lambda_2[RFS] + (1-p)\delta_{F2}[RFRF] + \delta_{L2}[RFR_L] - \mu[RFS] \\
&\quad - F_{V2}[RFS] + \nu_2[R_FV] \\
\frac{d}{dt}\{ R_L S \} &= p\delta_{F1}[RFS] - \delta_{L1}[R_L S] - \lambda_2[R_L S] + (1-p)\delta_{F2}[R_LR_F] + \delta_{L2}[R_LR_L] - \mu[R_L S] \\
&\quad - F_{V2}[R_L S] + \nu_2[R_LV] \\
\frac{d}{dt}\{ V S \} &= F_{V1}[SS] - \nu_1[VS] - \lambda_2[VS] + (1-p)\delta_{F2}[VRF] + \delta_{L2}[VRL] - \mu[VS] - F_{V2}[VS] + \nu_2[VV] \\
\\
\frac{d}{dt}\{ S E \} &= \lambda_2[SE] - \gamma_2[SE] - \mu[SE] \\
\frac{d}{dt}\{ R_F E \} &= \lambda_2[RFE] - \gamma_2[RFE] - \mu[RFE] \\
\frac{d}{dt}\{ R_L E \} &= \lambda_2[RE] - \gamma_2[RE] - \mu[RE] \\
\frac{d}{dt}\{ V E \} &= \lambda_2[VE] - \gamma_2[VE] - \mu[VE] \\
\\
\frac{d}{dt}\{ S I \} &= \gamma_2[SE] - r_2[SI] - \mu[SI] - \mu_F[SI] \\
\frac{d}{dt}\{ R_F I \} &= \gamma_2[RFE] - r_2[RFI] - \mu[RFI] - \mu_F[RFI] \\
\frac{d}{dt}\{ R_L I \} &= \gamma_2[RE] - r_2[RLI] - \mu[RLI] - \mu_F[RLI] \\
\frac{d}{dt}\{ V I \} &= \gamma_2[VE] - r_2[VI] - \mu[VI] - \mu_F[VI] \\
\\
\frac{d}{dt}\{ S R_F \} &= -\lambda_1[SRF] + (1-p)\delta_{F1}[RFRF] + \delta_{L1}[R_LR_F] + r_2[SI] - \delta_{F2}[SRF] - \mu[SRF] \\
&\quad - F_{V1}[SRF] + \nu_1[VRF] \\
\frac{d}{dt}\{ E R_F \} &= \lambda_1[SRF] - \gamma_1[ERF] - \mu[ERF] \\
\frac{d}{dt}\{ I R_F \} &= \gamma_1[ERF] - r_1[IRF] - \mu[IRF] - \mu_F[IRF] \\
\frac{d}{dt}\{ R_F R_F \} &= r_1[IRF] - \delta_{F1}[RFRF] + r_2[RFI] - \delta_{F2}[RFRF] - \mu[RFRF] \\
\frac{d}{dt}\{ R_L R_F \} &= p\delta_{F1}[RFRF] - \delta_{L1}[R_LR_F] + r_2[RLI] - \delta_{F2}[R_LR_F] - \mu[R_LR_F] \\
\frac{d}{dt}\{ V R_F \} &= F_{V1}[SRF] - \nu_1[VRF] + r_2[VI] - \delta_{F2}[VRF] - \mu[VS] \\
\\
\frac{d}{dt}\{ S R_L \} &= -\lambda_1[SR_L] + (1-p)\delta_{F1}[RFR_L] + \delta_{L1}[R_LR_L] + p\delta_{F2}[SRF] - \delta_{L2}[SRL] - \mu[SR_L] \\
&\quad - F_{V1}[SR_L] + \nu_1[VR_L] \\
\frac{d}{dt}\{ E R_L \} &= \lambda_1[SR_L] - \gamma_1[ER_L] - \mu[ER_L] \\
\frac{d}{dt}\{ I R_L \} &= \gamma_1[ER_L] - r_1[IR_L] - \mu[IR_L] - \mu_F[IR_L] \\
\frac{d}{dt}\{ R_F R_L \} &= r_1[IR_L] - \delta_{F1}[RFR_L] + p\delta_{F2}[RFRF] - \delta_{L2}[RFR_L] - \mu[RFR_L] \\
\frac{d}{dt}\{ R_L R_L \} &= p\delta_{F1}[RFR_L] - \delta_{L1}[R_LR_L] + p\delta_{F2}[R_LR_F] - \delta_{L2}[R_LR_L] - \mu[R_LR_L] \\
\frac{d}{dt}\{ V R_L \} &= F_{V1}[SR_L] - \nu_1[VR_L] + p\delta_{F2}[VRF] - \delta_{L2}[VR_L] - \mu[VS] \\
\\
\frac{d}{dt}\{ S V \} &= F_{V2}[SS] - \nu_2[SV] - \lambda_1[SV] + (1-p)\delta_{F1}[R_FV] + \delta_{L1}[R_LV] - \mu[SV] - F_{V1}[SV] + \nu_1[VV] \\
\frac{d}{dt}\{ E V \} &= \lambda_1[SV] - \gamma_1[EV] - \mu[EV] \\
\frac{d}{dt}\{ I V \} &= \gamma_1[EV] - r_1[IV] - \mu[IV] - \mu_F[IV] \\
\frac{d}{dt}\{ R_F V \} &= F_{V2}[R_FV] - \nu_2[R_FV] + r_1[IV] - \delta_{F1}[R_FV] - \mu[SV] \\
\frac{d}{dt}\{ R_L V \} &= F_{V2}[R_LV] - \nu_2[R_LV] + p\delta_{F1}[R_FV] - \delta_{L1}[R_LV] - \mu[SV] \\
\frac{d}{dt}\{ V V \} &= F_{V12}[SS] + F_{V1}[SV] - \nu_1[VV] + F_{V2}[VS] - \nu_2[VV]
\end{aligned} \tag{1}$$

The coefficients of the flow terms in the equations in Equation 1 are described in Table S1.2. $1/\gamma$ is the duration of the latent period and $1/\rho$ is the duration of the infectious period. μ is the natural death rate, applied by month of age

but constant for all individuals of the same year of age. The subscript i represents the virus to which the parameter refers.

Vaccination was modelled continuously as part of the differential equations for the system. The vaccination campaign was assumed to start on in mid-October (day 288) and last between 30 to 40 days. By the end of the vaccination campaign, a proportion of the susceptible population equal to the effective vaccine coverage for that strain in that age group (product of uptake and efficacy) was transferred to the vaccinated category. (These individuals did not necessarily remain in the vaccinated category, due to mortality and other model flows.) When individuals were vaccinated to two strains at once, with strain-specific efficacies it was necessary but non-trivial to determine the shared rate of vaccination. These calculations are described in Section 1.8.

$\lambda_i(t, m)$ represents the age dependent force of infection in the model on each monthly age group due to individuals who are infectious with virus i . The “ (t, m) ” is suppressed in the above equations for brevity but included here to emphasize the time- and age-dependence of this quantity and of the compartment populations. For an individual of m months of age, $\lambda_i(t, m)$ is defined as follows:

$$\begin{aligned}\lambda_1(t, m) &= z(t) \sum_{m'} \beta_{m, m'} [IS(t, m') + IR_F(t, m') + IR_L(t, m')], \\ \lambda_2(t, m) &= z(t) \sum_{m'} \beta_{m, m'} [SI(t, m') + R_F I(t, m') + R_L I(t, m')],\end{aligned}\tag{2}$$

where $\beta_{m, m'}$ is the transmission coefficient describing the rate of contact and probability of transmission from individuals of age m' to those of age m . The sums in square brackets represent all individuals of age m' at time t who are infectious with a particular virus. The term $z(t)$ is a sine wave function emulating the seasonal fluctuation in the force of infection:

$$z(t) = 1 + q \cdot \sin\left(\frac{2\pi(t - \varphi)}{365}\right)\tag{3}$$

where t is the number of days since the start of the simulation, q controls the amplitude and φ the phase of the wave.

These first order ordinary differential equations were numerically solved using a fourth-order Runge–Kutta method with adaptive step ¹⁴.

Structural assumptions

This section summarizes structural assumptions made in the model.

- All individuals, irrespective of influenza infection or immunity status, are subject to an age specific background mortality rate (mortality unrelated to influenza)
- The number of births per year is assumed to remain constant
- The population is stratified by age in months

- Aging occurs at the end of each month
- Individuals are born susceptible and remain so until infected or vaccinated
- The rate of infection is assumed to be population density-dependent, i.e. the transmission coefficient is assumed to remain unchanged as the total population size (N) fluctuates. The rate of infection is therefore assumed to be proportional to the number of infectious and the number of susceptible individuals
- The transmission coefficient between two age groups m and m' , $\beta_{m,m'}$, is also assumed to remain constant over time
- As the incidence of influenza follows a marked seasonal pattern, the magnitude of R_0 was assumed to vary sinusoidally around its mean, peaking in late December
- On infection, there is a latent period, during which individuals are infected, but not yet infectious. All infected individuals that survive the latent period progress to become infectious
- The duration of viral shedding was assumed to be uniform across all age bands
- A number of infectious cases each year arise as a result of imported infections
- All individuals that survive the infectious period clear the infection and enter the recovered state
- Recovered individuals are immune to further influenza infection by the same strain
- Recovered individuals lose their immunity over a time, as a result of the combined effects of viral antigenic drift and loss over time of immunological memory. In so doing, they return to the susceptible state for that strain
- Vaccination transitions individuals directly from the susceptible to the vaccinated state, where they are not susceptible to infection by those strains of influenza covered by the vaccine
- Vaccination has no effect on latently infected, infectious or recovered individuals. Vaccination of these individuals is however accounted for during the costing calculations
- Vaccinated individuals lose their immunity to an influenza subtype or lineage over a time, as a result of the combined effects of viral antigenic drift and loss over time of immunological memory. In so doing, they return to the susceptible state. The duration of vaccine-induced immunity is assumed, on average, to be much shorter than that due to naturally-acquired immunity
- Individuals who are infected (exposed and latently infected, or infectious) to one virus cannot be simultaneously infected with the other virus
- The model structure simulated two viruses simultaneously, to allow for modelling of cross-protective immunity; however, this capacity was not used as cross-protection was set to 0. The dynamics of each strain are assumed to be conceptually independent of any other strain except for the above assumption regarding simultaneous infection. (This assumption briefly removes individuals infected with one virus from the pool of individuals susceptible to the other virus, which will slow down an epidemic in that other virus, if it is occurring. The

strains are therefore not fully independent even if cross-protective immunity is set to 0. This assumption was thought justified as an infected patient's immune system would be working to eradicate the first virus (and therefore likely stop the second from taking hold), and individuals showing symptoms may reduce contact with others.)

- Having a susceptible compartment is necessary but not sufficient for a compartment to be affected by vaccination; in particular, vaccination was not modelled in the compartments in which infection is happening in the other virus (*SE*, *SI*, *ES*, *IS*). The assumption was that individuals move quickly through these compartments, and are unlikely to be vaccinated when they are ill
- Vaccination is assumed to be randomly distributed in any age group
- It is assumed that the only people who successfully change compartments upon vaccination are those who are susceptible; that is, the effects of vaccination in the other compartments are disregarded. A corollary of this assumption is that natural immunity to a virus is stronger than vaccine-induced immunity, and so individuals with natural immunity to a virus, who are vaccinated for it, do not change their status. For example, someone in SR_F who is vaccinated against both viruses will move to VR_F , not to VV .

1.5. Pre-existing immunity structure

It was necessary to estimate the proportion of the population in each of the disease states at the start of the model (the “pre-existing immunity structure”).

The transmission model was run forward for decades. For each virus, the virus behavior (e.g., a large peak, no epidemic), according to the GP consultation data ¹⁵ in the 2010/11-2011/12 seasons was considered. A starting season was chosen from the run-forward model if it and its following season approximated the behavior of the GP data. Parameter estimates used during this process are provided in Table S1.3-Table S1.4; these are based on previous model adaptations ¹⁶.

For each virus strain the proportion of the population that was immune (natural or vaccinated) at the start of the chosen season was recorded, and used as the proportion immune at the model's start. The resulting immunity structures are graphed in Figure S1.4.

For parsimony and to reduce the number of parameters sampled during the calibration stage, linear approximations were used to divide this proportion among the naturally immune (short- or long-term) and the vaccinated categories. Due to a short assumed duration of vaccine-induced immunity (Table S1.3) and a relatively low vaccination rate in children and young adults (Table S1.6), it was assumed only the >60 year age classes maintained an appreciable proportion with vaccine-induced immunity from one season to the next. To make this approximation was assumed that in the oldest year of age 100% of immune individuals were vaccinated, in the 60-year olds 0% of immune individuals were due to vaccination, and the proportion was increased linearly between these ages calculated at the midpoint of the age group. For the remaining seniors, and for children and young adults, the immune population was

split between short- and long-term immunity classes by assuming that the proportions of populations with short- and long-term immunity, R_S and R_L with durations d_S and d_L , respectively, were related via

$$\frac{R_L}{R_S} \approx \frac{d_L}{d_L + d_S} \cdot P(\text{long-term immunity}). \quad (4)$$

Table S1.3: Interim transmission parameter estimates: mean values were used for the simulation which generated the pre-existing immunity estimates used during the model calibration.

Parameter	Value
Forcing parameters	
Seasonal forcing offset (days from Jan 1)	264
Annual seed amount per monthly age band	0.1
Seasonal forcing magnitude	0.43
R0 parameters	
Transmission coefficient	Influenza A H1N1: 4.44 E-08 Influenza A H3N2: 5.95 E-08 Influenza B: 5.55 E-08
Latent period (days)	2
Infectious period (days)	2
Immunity parameters	
Probability of acquiring long-term immunity	0.4
Duration of initial naturally-acquired immunity (years)	Influenza A: 6 Influenza B: 21
Duration of long-term naturally-acquired immunity (years)	40
Duration of vaccine-induced immunity (years)	Influenza A: 1 Influenza B: 2
Vaccination parameters	
Vaccine campaign duration (days)	35
Vaccination season start (day of year)	288
Demographic parameters	
Live births per month	15,366.42




Figure S1.4: Pre-existing immunity structure.

Table S1.4: *Interim pre-existing immunity estimates, used for the simulation which generated the pre-existing immunity estimates used during the model calibration.*

Age group	A H1N1	A H3N2	B Victoria	B Yamagata
0–<1	0.01	0.04	0.06	0.02
1–<2	0.02	0.10	0.12	0.04
2–<5	0.05	0.17	0.14	0.12
5–<10	0.13	0.47	0.41	0.32
10–<15	0.25	0.62	0.50	0.47
15–<18	0.42	0.59	0.49	0.51
18–<20	0.53	0.53	0.50	0.52
20–<25	0.51	0.54	0.51	0.50
25–<30	0.40	0.58	0.57	0.52
30–<35	0.32	0.64	0.59	0.56
35–<40	0.33	0.59	0.58	0.55
40–<45	0.36	0.61	0.59	0.57
45–<50	0.41	0.60	0.63	0.62
50–<55	0.44	0.61	0.64	0.64
55–<60	0.41	0.61	0.65	0.65
60–<65	0.37	0.61	0.66	0.68
65–<70	0.37	0.63	0.65	0.72
70–<75	0.33	0.64	0.55	0.67
75–<80	0.33	0.56	0.46	0.61
80–<85	0.32	0.48	0.39	0.57
85–<90	0.46	0.43	0.37	0.55
90–<95	0.46	0.44	0.24	0.47
95–<100	0.44	0.39	0.17	0.41

1.6. Imported influenza

To emulate the observed influenza dynamics the model population was seeded with new infectious influenza cases ⁹. Cases were introduced annually into each one month age band between the ages of 5 and 50 years inclusive.

1.7. Mixing matrix

The age stratified mixing matrix, also known as a WAIFW matrix (“Who Acquires Infection From Whom”), was obtained from the Netherlands-specific section of the POLYMOD study, a large European study of age stratified daily contact rates ⁸. The standard error for each entry in the matrix was calculated using the recorded sample sizes, and an assumption that the error followed a Poisson distribution.

1.8. Vaccination

Vaccine efficacy

Efficacy against laboratory-confirmed influenza of the inactivated vaccine (IV) was obtained by age ¹¹ (Table S1.5). Vaccine efficacy in those 65 and older was assumed to be 50%, based on estimates of vaccine efficacy in preventing pneumonia, hospitalisations and deaths in elderly individuals living in care homes ¹⁷, with a slightly wider confidence interval than provided for younger adults ¹¹. The efficacy of LAIV is currently under debate. Randomized clinical trials in children have demonstrated a superior efficacy of LAIV as compared to the IV ¹¹, but this finding has not been confirmed in recent post-licensure studies ¹⁸⁻²⁰. Therefore, the efficacy of LAIV was assumed to be equal to IV in the main analysis and explored a higher efficacy LAIV using clinical trial data in the sensitivity analysis.

Table S1.5: Mean vaccine efficacy estimates (%).

Age group	Main analysis IV and LAIV		Sensitivity analysis LAIV	
	Mean	95% CI	Mean	95% CI
Children (0.5-<18)	48	(31, 61)	80	(70,87)
Adults (18-<65)	59	(50, 66)	--	--
Elderly (≥ 65)	50	(39, 59)	--	--

IV: Inactivated vaccine, LAIV: Live-attenuated influenza vaccine

Vaccine composition

Up to and including the 2013/14 season the model simulated trivalent vaccination and assumed the included influenza B lineage conformed to that recommended by the WHO ⁴.

Vaccine uptake

Uptake in the Netherlands was obtained from National Institute for Public Health and the Environment (RIVM) reports for 2010/2011 to 2013/14 ⁶ (Table S1.6).

Table S1.6: Influenza vaccine uptake used in the transmission model, 2010/2011-2013/14.

Age group	2010	2011	2012	2013
0.5–<2	2.1%	1.7%	1.2%	1.0%
2–<5	2.1%	1.7%	1.2%	1.0%
5–<10	4.1%	3.4%	2.9%	2.7%
10–<15	5.0%	4.3%	3.7%	3.5%
15–<18	5.0%	4.7%	4.0%	4.0%
18–<20	5.0%	4.7%	4.0%	4.0%
20–<25	3.9%	3.6%	3.3%	3.4%
25–<30	3.5%	3.2%	3.0%	3.1%
30–<35	4.7%	3.9%	3.5%	3.8%
35–<40	6.3%	5.4%	5.0%	4.9%
40–<45	8.4%	7.2%	6.5%	6.7%
45–<50	11.1%	10.0%	9.5%	9.4%
50–<55	16.0%	15.1%	13.8%	13.4%
55–<60	29.2%	26.0%	23.5%	22.6%
60–<65	63.8%	57.9%	52.1%	48.5%
65–<70	74.2%	69.2%	64.8%	63.1%
70–<75	79.0%	76.3%	72.9%	71.1%
75–<80	83.8%	80.8%	79.0%	77.9%
80–<85	84.5%	83.5%	82.9%	81.5%
85–<90	85.3%	83.2%	80.9%	80.9%
90–<95	83.0%	81.3%	82.1%	78.0%
95–<100	81.5%	75.7%	78.9%	70.2%

Uptake data were provided by RIVM ⁶ in 5-year age groups. Vaccination age groups were split at 2 years and 18 years of age in the transmission model to match efficacy estimate age categories.

Vaccination against two viruses simultaneously

For influenza type A, and for influenza B under quadrivalent vaccination, individuals susceptible to both circulating strains could be vaccinated against both at once. As vaccination was applied continuously, this necessitated calculating the shared rate of vaccination. The efficacy of the virus to each strain could differ so this calculation was not symmetrical.

Given the time t_0 of the start of the vaccination campaign, and a campaign of length Δt_i , at the end of the campaign a proportion p_i of those originally susceptible to virus i will have been vaccinated (Figure S1.5A).




Figure S1.5: The proportion of the original susceptible population vaccinated to each virus at time $t_0 + \Delta t_v$, given an originally unvaccinated population.

The corresponding rates of vaccination are then $r_i = -\ln(1 - p_i)/\Delta t_v$, for $i = 1, 2$ (Figure S1.5B). Both of these flows contribute to the quantity of interest: the rate of successful vaccination to both viruses simultaneously. In Figure S1.5B the variable φ represents this quantity.

In the absence of other flows and assuming no vaccinated individuals to start, we have from Figure S1.5B that

$$SS' = -(r_1 + r_2 - \varphi)SS \quad (5)$$

$$VV' = \varphi SS \quad (6)$$

Equation (1) yields $SS(t) = SS(t_0)e^{-(r_1+r_2-\varphi)(t-t_0)}$; substitution into equation (2) and assuming $VV(t_0) = 0$ gives

$$VV(t) = \frac{\varphi SS(t_0)}{(r_1 + r_2 - \varphi)} [1 - e^{-(r_1+r_2-\varphi)(t-t_0)}] \quad (7)$$

Using Figure S1.5A, $VV(t_0 + \Delta t_v) = p_1 p_2 SS(t_0)$. Substituting into equation (3) and rearranging gives the equation in one unknown (φ),

$$p_1 p_2 = \frac{\varphi}{(r_1 + r_2 - \varphi)} [1 - e^{-(r_1+r_2-\varphi)\Delta t_v}] \quad (8)$$

Equation (4) does not have an analytical solution; whenever necessary (e.g. if one vaccination rate was non-zero) the solution for φ was therefore determined numerically, using Newton's method.

1.9. Influenza-attributable mortality

In addition to the background mortality rate mortality attributable to influenza was modelled. At the end of each day in the model, a small proportion of individuals in all compartments with infectious status were removed from the model.

For the calibration stage of the model this daily proportion was calculated by using interim estimates of the probability of death given influenza infection from a previous model ²¹ (Table S1.7), divided by the length of the infectious period. Given the low probabilities, converting to a rate, under the assumption of a constant risk, then calculating the probability over one day produced nearly identical values. These estimates (Table S1.7) were placeholder values used during the model calibration phase, and were later replaced by samples from Netherlands-specific parameter distributions as described in Section 1.3.

Table S1.7: Placeholder values for the probability of death given influenza infection (used for all influenza strains) used during the calibration phase.

Age category	Probability of death given influenza infection	Age category	Probability of death given influenza infection
0–<1	0.000013	50–<55	0.000096
1–<5	0.000003	55–<60	0.000185
5–<10	0.000001	60–<65	0.000564
10–<15	0.000001	65–<70	0.002374
15–<20	0.000003	70–<75	0.003094
20–<25	0.000004	75–<80	0.006778
25–<30	0.000008	80–<85	0.017642
30–<35	0.000011	85–<90	0.035290
35–<40	0.000018	90–<95	0.057720
40–<45	0.000033	95–<100	0.114835
45–<50	0.000069		

2. Calibration

The deterministic model was run for each simulation in the probabilistic sensitivity analysis (PSA). The main innovation of this study was that transmission inputs were sampled in addition to clinical and economic inputs, in a full PSA that incorporated the uncertainty in all parameters, epidemiological, clinical and economic.

For computational convenience, the PSA was split into two stages:

- i. Calibration
- ii. Expected net benefit (ENB) analysis.

The transmission inputs were sampled while calibrating the model to available data on influenza epidemiology. Calibrated inputs from this stage were kept and re-run over a longer time horizon in the expected net benefit analysis stage of the PSA, with clinical and later economic inputs sampled and applied.

During the calibration, transmission inputs were given initial input distributions. A sample was drawn for each simulation and the model was integrated. The set of transmission inputs for any simulation that met all pre-defined criteria was recorded for re-use during the ENB analysis.

2.1. Calibration data sources

The main data source for the model calibration was a set of Netherlands-specific general practitioner (GP) consultation rates obtained from a regression of influenza-like illness (ILI) data against laboratory-confirmed influenza reports¹⁵. These rates were stratified by influenza strain, age group (0-<5, 5-<20, 20-<60 and ≥60 years), and season (2010/11 – 2013/14). In the regression study¹⁵, the unspecified influenza-positive samples were redistributed to influenza subtype/lineage to match the subtype/lineage-specific consultation rates match the total influenza-attributable ILI consultation rates. In the current analysis, however, we used subtype/lineage-specific consultation rates from the regression analysis in which the unspecified influenza-positive samples were not redistributed to influenza subtype/lineage.

A supplementary data source used for one of the fit criteria (described below) was the WHO Flunet surveillance⁵.

2.2. Transmission parameter sampling distributions

The transmission parameters sampled for each simulation of the calibration stage are summarised in Table S1.8, along with their sampling distributions.

Table S1.8 Transmission parameters sampled in the calibration and their sampling distributions.

Input	Stratified by [‡]	Distribution	Min	Max
Forcing parameters				
Seasonal forcing magnitude		Uniform	0	0.99
Annual seed amount per monthly age band		Uniform	0.01	1
Seasonal forcing offset (days from Jan 1)		Uniform (integer)	234	294
R0 parameters				
Transmission coefficient	Virus	Uniform	2.76E-08	8.29E-08
Latent period (days)	Virus	Uniform	0.01	3
Infectious period (days)	Virus	Uniform	0.5	5
WAIFW matrix	Age of contact, Age of participant	Uniform	See text	
Immunity parameters				
Duration of initial naturally-acquired immunity (years)	Virus	Uniform	0.5	Influenza A: 10 Influenza B: 30
Duration of long-term naturally-acquired immunity (years)	Virus	Uniform	10	70
Probability of acquiring long-term immunity	Virus type	Uniform	0	1
Duration of vaccine-induced immunity (years)	Virus	Uniform	0.5	3
Pre-existing immunity scaler	Virus	Uniform	0.25	Virus-dependent*; ≤2.35
Vaccination parameters				
Vaccine efficacy	Age, Virus, Vaccine	Lognormal	See text	
Vaccination campaign duration (days)		Uniform (integer)	30	40
Probabilities				
Probability of symptoms given infection		Beta: Mean = 0.669, SE = 0.0413	0	1

[‡] Inputs with blank cells were sampled as scalars.

* Maximum allowed pre-existing immunity in any age group = 100%.

Each entry of the WAIFW matrix was sampled independently. Standard errors were estimated for each WAIFW entry by assuming the contact counts followed a Poisson distribution (entries with a value of 0 were assumed equal to 0.01 for the SE calculations so the values would not be fixed during sampling). A range for each entry was defined as $entry \pm 3 \times SE(entry)$, and the value was sampled uniformly from this range (a negative lower limit was set to 0).

The relative risk (RR, defined as $1 - \text{efficacy}$) for each age group and vaccine has been estimated based on a lognormal distribution¹¹. This $\ln(\text{RR})$ was therefore sampled for each simulation and converted to efficacy. A separate sample was produced for each of the age groups (Table S1.5).

For each virus, to encapsulate uncertainty in the pre-existing immunity proportions while maintaining the general age profile (Figure S1.4), the proportion immune in individuals under 20 years of age was multiplied by a scaling coefficient (the youngest age categories were those with the most contacts⁸). The overall structural shape was therefore maintained in these age groups, while the scale factor for each virus was sampled uniformly, over a range calculated to prohibit obtaining a proportion immune > 1 (Table S1.8).

Estimates of vaccination uptake were not sampled.

2.3. Fit criteria

The criteria given in the main methods are repeated below:

- I. Probability of consulting a GP given influenza infection could not be unrealistic.
- II. For each strain, GP consultations fell within a pre-defined Poisson deviance of the regression results over the 2010/11 – 2013/14 seasons.
- III. SD/mean ratio of epidemic peaks for each virus not unrealistically low
- IV. Low incidence pre-influenza season (before September surveillance start) and between influenza seasons

Criterion I: GP probability

The GP consultation rates from the regression results were converted to total numbers of GP consultations, by virus and age group, over the 2010/11 – 2013/14 influenza seasons. The total modelled incidence of infection was calculated, by virus and age group, over the 2010/11 – 2013/14 influenza seasons. The probability of a GP consultation given influenza infection (“ $P(\text{GP} | \text{infection})$ ”) was then calculated as the ratio of these two quantities.

Depending on the cumulative number of infections, this probability could vary widely. The simulation was defined to meet criterion I if the following two conditions were met:

1. $P(\text{GP} | \text{infection}) < P(\text{symptoms} | \text{infection})$
2. $P(\text{GP} | \text{infection}) \geq 0.01$.

Both conditions were applied to each virus and to each age group (0-<5, 5-<20, 20-<60 and ≥ 60 years).

Criterion II: fit to data

This criterion was applied by age group to each of the four modelled influenza strains over the 2010/11 to 2013/14 seasons. Each virus was tested separately.

Modelled cumulative incidence of infection was multiplied by $P(\text{GP} \mid \text{infection})$ described above, then converted to seasonal rates of GP consultations per 100,000 population and compared to the GP regression results. For each of the four seasons (2010/11 through 2013/14), for each of the four age groups used in the regression (0-4, 5-20, 20- <60 and ≥ 60 years) the Poisson deviance was calculated, defined for model result M and data point D as:

$$\text{deviance} = 2 \left[D \ln \left(\frac{D}{M} \right) - D + M \right]. \quad (9)$$

By testing various deviance values, it was determined that a limit of 2000 for each virus struck a balance between the accuracy of those simulations meeting the criteria (approximately within the standard error of the regression results) and the time taken to obtain a sufficiently large number of fits to conduct a probabilistic sensitivity analysis.

Criterion III: SD/mean ratio

In addition to matching the short-term GP data from the regression, the temporal pattern of the modelled influenza dynamics should emulate patterns observed in practice.

To mitigate year-on-year differences in proportions presenting and reported (emergent in the absolute scale of the surveillance report graphs), the ratio between the standard deviation and mean of the cumulative seasonal reports over a number of influenza seasons was calculated as a proxy for this temporal pattern.

WHO Flunet surveillance data ⁵ for various countries were considered (the Netherlands, Belgium, France, Germany and the UK). The minimum SD/mean ratio over all of these countries, calculated for all influenza, was around 0.5, depending on the time period considered. A lower bound of 0.25 was enforced on the SD/mean ratio for each influenza strain; this conservative heuristic prevented unrealistic runs with nearly the same incidence each season.

Criterion IV: Low pre-seasonal incidence

Initial test runs of the calibration revealed that an unreasonably high value for the influenza R_0 could sometimes produce a low deviance against the data: an epidemic could begin as soon as infectious cases were seeded, then subside before the modelled seasonal influenza surveillance started during week 40.

Limits imposed on R_0 , implemented indirectly through the transmission coefficient, latent period, and infectious period, would have skewed their uninformed input distributions and affected their joint sampling distribution. Instead, a pre-seasonal incidence limit of 160,000 (possibly asymptomatic) infections, approximately 1% of the population, was imposed on all viruses in their first season of circulation.

3. Expected net benefit analysis

3.1. Vaccination strategies

To assess the impact of paediatric vaccination a variety of vaccination strategies were run. These strategies were based on combinations of the following possibilities:

- TIV or QIV in those <2 or ≥ 18 years of age
- TIV or Q-LAIV in those 2-17
- Uptake level in those 2-17: latest available or based on assumptions

As the efficacy of IV and LAIV was assumed to be equal, the results of the Q-LAIV strategy in children aged 2-17 years represented also the scenario of QIV in children. In the sensitivity analysis we explored scenarios in which LAIV had a higher efficacy than IV (denoted as Q-LAIV+).

In children <2 years of age and in adults and the elderly, the vaccine uptake was unchanged, with the latest data (2013/14 season) ⁶ carried forward in each year of the simulation and not sampled in the PSA. The latest data was also carried forward in those paediatric age groups whose uptake was not altered based on scenario assumptions.

From the 2015/16 season onwards the vaccination scenarios diverged: in scenarios with increased uptake, the new uptake was implemented from this season onwards, while quadrivalent scenarios vaccinated both influenza A subtypes and both influenza B lineages each season. Trivalent scenarios followed a random pattern: each season, the B Yamagata lineage was vaccinated with a probability of 50%. The B Victoria lineage was vaccinated if and only if Yamagata was not. The resulting pattern was used for trivalent vaccination in all scenarios and all simulations.

All vaccination scenarios are listed in Table S1.9.

Table S1.9: Vaccination strategies

#	Scenario name	Vaccine in non-paediatric target groups		Vaccine in paediatric target groups			Uptake of paediatric programme		
		TIV	QIV	TIV	Q-LAIV	Q-LAIV ^{+b}	2-6y	2-12y	2-17y
1	No vaccination	-	-				0	0	0
2	TIV	X					a	a	a
3	QIV		X				a	a	a
4	TIV/TIV in 20% of 2–6y	X		X			20%	a	a
5	TIV/TIV in 20% of 2–12y	X		X			20%	20%	a
6	TIV/TIV in 20% of 2–17y	X		X			20%	20%	20%
7	TIV/TIV in 50% of 2–6y	X		X			50%	a	a
8	TIV/TIV in 50% of 2–12y	X		X			50%	50%	a
9	TIV/TIV in 50% of 2–17y	X		X			50%	50%	50%
10	TIV/TIV in 80% of 2–6y	X		X			80%	a	a
11	TIV/TIV in 80% of 2–12y	X		X			80%	80%	a
12	TIV/TIV in 80% of 2–17y	X		X			80%	80%	80%
13	TIV/Q-LAIV in 20% of 2–6y	X			X		20%	a	a
14	TIV/Q-LAIV in 20% of 2–12y	X			X		20%	20%	a
15	TIV/Q-LAIV in 20% of 2–17y	X			X		20%	20%	20%
16	TIV/Q-LAIV in 50% of 2–6y	X			X		50%	a	a
17	TIV/Q-LAIV in 50% of 2–12y	X			X		50%	50%	a
18	TIV/Q-LAIV in 50% of 2–17y	X			X		50%	50%	50%
19	TIV/Q-LAIV in 80% of 2–6y	X			X		80%	a	a
20	TIV/Q-LAIV in 80% of 2–12y	X			X		80%	80%	a
21	TIV/Q-LAIV in 80% of 2–17y	X			X		80%	80%	80%
22	QIV/Q-LAIV in 20% of 2–6y	X			X		20%	a	a
23	QIV/Q-LAIV in 20% of 2–12y	X			X		20%	20%	a
24	QIV/Q-LAIV in 20% of 2–17y	X			X		20%	20%	20%
25	QIV/Q-LAIV in 50% of 2–6y	X			X		50%	a	a
26	QIV/Q-LAIV in 50% of 2–12y	X			X		50%	50%	a
27	QIV/Q-LAIV in 50% of 2–17y	X			X		50%	50%	50%
28	QIV/Q-LAIV in 80% of 2–6y	X			X		80%	a	a
29	QIV/Q-LAIV in 80% of 2–12y	X			X		80%	80%	a
30	QIV/Q-LAIV in 80% of 2–17y	X			X		80%	80%	80%
31	TIV/Q-LAIV+ in 20% of 2–6y		X			X	20%	a	a
32	TIV/Q-LAIV+ in 20% of 2–12y		X			X	20%	20%	a
33	TIV/Q-LAIV+ in 20% of 2–17y		X			X	20%	20%	20%
34	TIV/Q-LAIV+ in 50% of 2–6y		X			X	50%	a	a
35	TIV/Q-LAIV+ in 50% of 2–12y		X			X	50%	50%	a
36	TIV/Q-LAIV+ in 50% of 2–17y		X			X	50%	50%	50%
37	TIV/Q-LAIV+ in 80% of 2–6y		X			X	80%	a	a
38	TIV/Q-LAIV+ in 80% of 2–12y		X			X	80%	80%	a
39	TIV/Q-LAIV+ in 80% of 2–17y		X			X	80%	80%	80%
40	QIV/Q-LAIV+ in 20% of 2–6y		X			X	20%	a	a

#	Scenario name	Vaccine in non-paediatric target groups	Vaccine in paediatric target groups	Uptake of paediatric programme		
41	QIV/Q-LAIV+ in 20% of 2–12y	X	X	20%	20%	^a
42	QIV/Q-LAIV+ in 20% of 2–17y	X	X	20%	20%	20%
43	QIV/Q-LAIV+ in 50% of 2–6y	X	X	50%	^a	^a
44	QIV/Q-LAIV+ in 50% of 2–12y	X	X	50%	50%	^a
45	QIV/Q-LAIV+ in 50% of 2–17y	X	X	50%	50%	50%
46	QIV/Q-LAIV+ in 80% of 2–6y	X	X	80%	^a	^a
47	QIV/Q-LAIV+ in 80% of 2–12y	X	X	80%	80%	^a
48	QIV/Q-LAIV+ in 80% of 2–17y	X	X	80%	80%	80%

^a: 2013/2014 influenza uptake (“latest data”), ^b: In Q-LAIV+ scenario, the efficacy of Q-LAIV was assumed to be higher as compared to the inactivated influenza vaccine in accordance to clinical trial data ¹¹.

3.2. Clinical outcomes

The immediate output of the model integration was incidence of infection. This incidence was converted to clinical outcomes using age-specific risk functions.

3.2.1. Clinical outcome data sources

Data were obtained from the published literature from the following sources.

- Probability of symptoms given influenza infection ²²
- Netherlands-specific estimates of the relationship between respiratory-associated hospitalization and ILI GP report incidence ²³.
- Netherlands-specific estimates of the average annual number of influenza-attributable deaths ²⁴.

3.2.2. Risk functions

This section describes the calculations of the risk functions. The functions and their sampling distributions (Section 3.2.3) are provided in Table S1.10.

Symptomatic infections

The model output was incidence of infection, irrespective of whether or not these infections were symptomatic. This output was converted into symptomatic infections by multiplying by an estimate of the probability of symptoms given influenza infection ²². In the absence of other data this probability was assumed constant across all ages.

GP consultations

The probability of a GP consultation given infection was calculated as part of the calibration, as described in Section 1.2. For each simulation this probability, by virus and age, was calculated as the ratio of the total number of GP

consultations (from the regression), divided by the total modelled incidence of infection over the 2010/11 – 2013/14 influenza seasons.

Hospitalizations

To calculate hospitalizations, risk functions were applied in stages. First, estimates were obtained from the literature of the relationship between respiratory-associated hospitalization and ILI GP report incidence²³. The age-stratified regression coefficients calculated over the 1999/2000-2004/2005 seasons were used as the probability of a hospitalization given a GP consultation ($P(\text{hospitalization} | \text{GP})$).

These estimates were multiplied by the probability of a GP consultation given infection ($P(\text{GP} | \text{infection})$) calculated during the model calibration. This probability was calculated using regression and model results for the 2010/11-2013/14 seasons. It was assumed that the probability of a hospitalization given a GP consultation did not vary greatly between 1999-2005 and 2010-2014.

Mortality

Ages-stratified estimates of the average annual number of influenza-attributable deaths over the 1999/2000 through 2008/2009 seasons were obtained from the literature; the values from the sensitivity analysis were used, which attributed pneumonia and influenza deaths instead of all-cause mortality²³. These numbers were divided by the average annual number of infections as output by the calibrated transmission model over the 2010/2011-2013/2014 seasons, averaged over all runs in the calibrated model.

To adjust for the discrepancy in time periods a correction factor was defined using the GP regression output. The average number of GP consultations (total of influenza A and influenza B) was calculated for 2003/2004-2008/2009 and 2010/2011-2013/2014 the using the regression coefficients and the average number of influenza laboratory reports. (The starting season of 2003/2004 was the earliest season available in the regression results.) The ratio of these averages was used to scale the model-output number of infections from the later time period, to what it could be expected to be in the earlier time period, as follows:

$$P(\text{death} | \text{infection}) = \text{Deaths}_{1999-2009} / \left(\text{Incidence}_{2010-2014} \frac{\text{GP consultations}_{2003-2009}}{\text{GP consultations}_{2010-2014}} \right) \quad (10)$$

All quantities in the right-hand side of the above equation are average annual values.

3.2.3. Risk function sampling distributions

All clinical outcome probabilities were sampled from a beta distribution with means calculated as described in Section 3.2.2. This section describes the calculations of the standard errors. The risk functions and their sampling distributions are provided in Table S1.10.

Symptomatic infections

The probability of symptoms given infection was sampled during the calibration from a beta distribution, with mean equal to a published estimate in young adults of 0.669²² and the standard error (SE) was calculated using the provided confidence interval. The samples used in the calibration were re-used for the ENB analysis.

GP consultations

The probability of a GP consultation given infection was calculated during the model calibration. The probabilities therefore varied intrinsically for each simulation in the model calibration due to the different incidence of infection for each sample of the transmission parameters. The same values as calculated in the calibration were therefore used for the ENB analysis.

Hospitalizations

The overall probability of hospitalization given influenza infection was not sampled directly, as it was the product of two quantities: P(hospitalization | GP) and P(GP | infection). The latter quantity was intrinsic to the model calibration, as discussed above. The probability of hospitalization given GP consultation was sampled during the ENB analysis from a beta distribution, with mean equal to the published estimates. The overall SE for each age group was not reported so it was calculated by finding the SE of the average of the annual estimates; these annual estimates reported their SEs²³.

Mortality

The probability of death given influenza infection was sampled during the ENB analysis from a beta distribution. The SE was calculated by combining the variances of all terms in Equation (10); for the number of deaths²⁴ a variance of 10% of the mean was assumed.

Table S1.10: Risk function parameters sampled during the ENB stage and their sampling distributions.

Risk function and age group	Mean estimate	Standard error	Distribution
Probability of symptoms given infection (all ages)	0.669	0.04133	Beta
Probability of hospitalization given influenza-attributable GP consultation*			
0-<5	0.0148	0.000879	Beta
5-<20	0.0040	0.000264	Beta
20-<65	0.0062	0.000752	Beta
65-<100	0.0352	0.002182	Beta
Probability of death given infection			
0-<45	0.000003	2.96E-07	Beta
45-<65	0.000035	0.000004	Beta
65-<75	0.000320	0.000049	Beta
75-<100	0.003502	0.000534	Beta

GP: General practitioner. * These probabilities were multiplied by the probabilities of a GP consultation given infection, which were intrinsic to the calibrated model (calculated during the calibration).

3.2.4. Additional application of fit criteria

After the calibration stage, when the model was run forward in the ENB analysis to calculate clinical and economic outcomes, the background mortality rate attributable to influenza was sampled from an input distribution as described in Section 3.2.3. This rate has a small effect on influenza transmission in the model as it removes individuals from the model population.

A small proportion of the calibrated model simulations barely met the fit criteria, and with the influenza incidence slightly altered by these new mortality probability samples, approximately 4% of simulations no longer met all criteria. These simulations were excluded from the clinical and economic results of the ENB analysis and retroactively excluded from summaries of the calibrated model.

3.3. Economic outcomes

3.3.1. Costs

The analysis adopted a societal perspective and included direct healthcare costs, indirect healthcare costs, patient costs, and productivity losses. All cost-related inputs are shown in Table S1.11 and are presented in 2017 euros (€). Costs from other years were converted to this base year using the Dutch Consumer Price Index ²⁵.

GP costs for children under 10 years of age were estimated using data from a Dutch web-based survey among parents of children 0–4 years of age with an influenza-like illness (ILI) episode ²⁶. This estimate includes costs of GP consultations, prescribed medication, and laboratory costs. GP costs of patients aged ≥ 10 years were based on patients with a lower-respiratory infection aged ≥ 18 years ²⁷. This estimate includes costs due to GP consultations, prescribed medication, and medical specialist consultations up to a maximum of 28 days after the onset of symptoms. Lengths of stay for influenza-related hospitalizations and the proportion of days on the intensive care unit (ICU) were based on Dutch healthcare claims of patients with hospitalized community-acquired pneumonia ²⁸. Total costs per stay were obtained by multiplying the length of stay with standardized costs per bed day from the Dutch cost-effectiveness guideline ²⁹.

Indirect healthcare costs are the lifetime healthcare costs unrelated to influenza of averted premature influenza-associated deaths. Indirect healthcare costs were estimated using the life expectancy at age of death based on life table methodology (see Section 3.3.2) and healthcare costs per year from the Practical Application to Include Disease Costs (PAID) tool ³⁰. As the tool includes costs for men and women separately, weighted averages were calculated using the gender distribution per age group of the Dutch 2010 population. To avoid double counting, healthcare costs related to pneumonia and influenza were excluded.

Patient costs of non-medically attended cases consist of over-the-counter (OTC) medication. OTC costs were based on the drug use of non-medically attended ILI cases from a flu survey in Belgium ³¹ multiplied with Dutch standardized treatment guidelines and drug costs ^{32,33}. Patient costs of medically attended cases were based on

patients with lower-respiratory tract infections aged ≥ 18 years and included OTC medication and travel costs to the GP and the medical specialist ²⁷. Patient costs of hospitalized cases were based on trial data from hospitalized community-acquired pneumonia cases and included costs of OTC medication and travel costs to the hospital ³⁴.

Productivity losses of non-medically attended and medically attended patients were estimated using data from the Great Influenza Survey (GIS), a Dutch internet-based system that monitored influenza-like-illness (ILI) during the winter season on the basis of self-reporting (see Friesema et al.³⁵ for more details). Work absence per ILI episode of employed participants was extracted and stratified by age and by GP consultation status. For hospitalized cases we assumed that the duration of absence was equal to the length of stay in the hospital. Missed work days were converted to costs using age-specific labour participation rates ³⁶, average number of working hours per day ³⁷, and the average cost per working hour ²⁹. For influenza deaths we estimated productivity losses using the friction method ³⁸, which limits the number of working days lost to a friction period. We used a friction period of 85 days ²⁹.

We included productivity losses of parental work loss only for children aged under 10 years. For non-hospitalized cases we based the parental work loss on a Dutch web-based survey among parents of children aged 0–4 years having an influenza-like illness (ILI) episode ²⁶. For hospitalized cases we used data from young children who were admitted with an RSV infection ³⁹. These durations of absence were multiplied with the productivity loss per working day as estimated for adults aged 24–45 years.

Table S1.11: Cost inputs (€, 2017)

Parameter	Deterministic	Standard error	Distribution	Reference
Direct health-care costs				
GP visit (€)				
0–<10	52.19	1.55	Gamma	Enserink, 2014 ²⁶
≥10	82.86	2.69	Gamma	Mangen, 2015 ²⁷
Hospitalization (length of stay in days)				
0–<10	3.60	0.030	Normal	Rozenbaum, 2015 ²⁸
10–<18	4.56	0.155	Normal	
18–<25	5.18	0.046	Normal	
45–<60	6.31	0.053	Normal	
60–<75	7.44	0.058	Normal	
≥75	7.95	0.051	Normal	
Proportion of hospitalized days on ICU				
0–<10	0.42%			Rozenbaum, 2015 ²⁸
10–<18	1.60%			
18–<45	7.38%			
45–<60	8.88%			
60–<75	8.51%			
≥75	4.29%			
Cost per hospitalized day				
General ward (€)				
0–<18	642			Dutch CE guideline, 2016 ²⁹
≥18	487			
ICU ward (€)	2,062			
Indirect health-care costs				
Costs per averted death (€) ^a				
0–<2	65,514			Statistics Netherlands, 2014 ⁴⁰ ; Van Baal, 2011 ³⁰
2–<5	67,939			
5–<10	73,095			
10–<18	84,710			
18–<25	93,829			
25–<45	110,290			
45–<60	139,335			
60–<75	155,457			
≥75	90,155			
Patient costs				
Non-medically attended (€)				
	7.04	0.16	Gamma	Bilcke, 2014 ³¹
Medically attended (€)				
	21.45	1.97	Gamma	Mangen, 2015 ²⁷
Hospitalized (€)				
	128.21	25.58	Gamma	Van Werkhoven, 2017 ³⁴
Productivity losses				

Case (days of absence)					
Non-medically attended					GIS data, employed persons only
15-<25	3.29	0.15	Normal		
25-<45	3.41	0.04	Normal		
45-<65	3.89	0.06	Normal		
≥65	3.49	0.17	Normal		
Medically attended (days of absence)					GIS data, employed persons only
15-<25	5.19	0.30	Normal		
25-<45	6.20	0.12	Normal		
45-<65	6.88	0.16	Normal		
≥65	5.88	0.22	Normal		
Hospitalized	Duration of hospitalization				Assumption
Mortality	85				Dutch CE guideline, 2016 ²⁹
Caregiver (days of absence) ^b					
Non-hospitalized	0.61	0.078	Normal		Enserink, 2014 ²⁶
Hospitalized	2.00	0.26	Normal		Miedema, 2001 ³⁹
Labor participation rate	Age-specific				Statistics Netherlands, 2016 ³⁶
Productivity losses per day (€)					Statistics Netherlands, 2014 ⁴⁰ ; CE manual, 2016 ²⁹
15-<18	28				
18-<25	88				
25-<45	203				
45-<60	190				
60-<75	48				
≥75	0				
Caregiver	203				Assumed equal to 25-<45 age-group

CE: Cost-effectiveness, GIS: Great influenza survey, GP: General practitioner

^a: Includes 4% annual discount rate, ^b: only applied for 0-9 year-olds.

3.3.2. QALY loss

QALY loss by clinical outcome status is shown in Table S1.12. QALY loss for medically attended influenza was based on quality of life data of patients aged ≥18 years with a lower respiratory tract infection. Quality of life data of up to 4 weeks after disease onset was used, measured by the validated EuroQol-5D (EQ-5D) instrument ²⁷. The EQ-5D is a descriptive system that comprises five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and this instrument is recommended for use in cost-effectiveness analysis by the Dutch cost-effectiveness guideline ²⁹. We estimated the QALY loss of non-medically attended influenza cases by adjusting the QALY loss of medically attended influenza using data from a health survey in Belgium ³¹. In this study, the QALY loss of medically attended and medically unattended ILI was estimated at 0.006 and 0.005, respectively, suggesting that the QALY loss of medically attended ILI was 1.2 times higher than medically unattended ILI. The QALY loss of hospitalized influenza was based on EQ-5D data from community-acquired pneumonia patients aged ≥65 years ⁴¹.

QALY loss of influenza-related premature deaths was estimated using the forecasted life expectancy of an average person at the age of death in the year 2024 ⁴⁰, which was subsequently converted to QALYs using Dutch EQ-5D population norms by age ⁴².

Table S1.12: QALY loss inputs

Parameter	Deterministic	Standard error	Distribution	Reference
Non-medically attended	0.0038	0.00043	Normal	Medically attended influenza adjusted using the QALY loss ratio of non-medically attended versus medically intended influenza-like illness from Bilcke, 2014 ³¹
Medically attended	0.0045	0.00051	Normal	Mangen, 2015 ²⁷
Hospitalized	0.0118	0.00030	Normal	Mangen, 2013 ⁴¹
Death ^a				Statistics Netherlands, 2014 ⁴⁰ ; Versteegh, 2016 ⁴²
0–<2	43.8			
2–<5	42.8			
5–<10	41.5			
10–<18	39.1			
18–<25	36.2			
25–<45	28.7			
45–<60	20.7			
60–<75	12.9			
≥75	4.4			

^a: Includes a 1.5% annual discount rate

3.4. Sensitivity analysis

We performed various univariate sensitivity analyses for the strategy of vaccination of children aged 2–17 years using Q-LAIV, while other age groups were vaccinated with TIV. For vaccine price, we varied the price between €3.59 (the price of TIV ⁴³) and €20.92 (the US CDC list price of Q-LAIV ⁴⁴, converted to euros using purchasing power parities ⁴⁵). We also present scenarios in which the healthcare payer’s perspective was adopted (including only direct and indirect healthcare costs) or in which indirect healthcare costs were excluded. With regard to productivity losses, we explored a scenario in which the productivity losses of premature deaths were valued according to the human capital approach (Table S1.13). This approach includes all productivity losses until the age of retirement.

As the life expectancy of the general population may not be representative for the estimation of the number of life years lost due to influenza-related death (patients that die due to influenza may have a health status that is below the population’s average), we also included a scenario in which life expectancy of premature influenza-related deaths was assumed to be half the life-expectancy of the general population at that age. Furthermore, we explored a

scenario in which we used a higher QALY loss per influenza case based on estimates from Lugner et al. ⁴⁶ (Table S1.13).

We also present undiscounted outcomes and outcomes using equal discount rates for costs and effects of 4% and 1.5%.

Table S1.13: Input values of the univariate sensitivity analysis

Parameter	Deterministic
Human capital approach (€) ^a	
0-<2	466,104
2-<5	524,973
5-<10	616,496
10-<18	825,250
18-<25	944,737
25-<45	787,069
45-<60	328,828
60-<75	10,128
≥75	-
QALY loss based on Lugner et al. ⁴⁶	
Non-hospitalized	0.010
Hospitalized	0.217

^a: Includes a 4% annual discount rate

4. References

1. Statistics Netherlands. Population; sex, age and marital status, 1 January 2010
<https://statline.cbs.nl/Statweb/publication/?DM=SLLEN&PA=7461eng&D1=0&D2=0&D3=0-100&D4=60&LA=EN&HDR=T,G3&STB=G1,G2&VW=T>. Accessed at 1 Jan 2015.
2. Statistics Netherlands. Birth; key figures 2010
<https://statline.cbs.nl/Statweb/publication/?DM=SLLEN&PA=37422eng&D1=0-2&D2=60&LA=EN&HDR=T&STB=G1&VW=T>. Accessed at 1 Jan 2015.
3. Statistics Netherlands. Life expectancy; gender, age (per year and period of five years) 2010
<https://statline.cbs.nl/Statweb/publication/?DM=SLNL&PA=37360ned&D1=0&D2=0&D3=a&D4=89&HDR=G1,T&STB=G2,G3&VW=T>. Accessed at 1 Jan 2015.
4. World health Organization. Influenza vaccine viruses and reagents 2015
<https://www.who.int/influenza/vaccines/virus/en/>. Accessed at 1 Jan 2016.
5. World Health Organization. Flunet database 2015
https://www.who.int/influenza/gisrs_laboratory/flunet/en/. Accessed at 1 Jan 2016.
6. National Institute for Public Health and the Environment. Monitoring vaccination coverage national program for flu prevention [In Dutch] 2015 <https://www.rivm.nl/monitoring-vaccinatiegraad-nationaal-programma-grieppreventie-npg>. Accessed at 1 Jan 2016.
7. National Institute for Public Health and the Environment. LCI guideline Influenza [In Dutch] 2011
<https://lci.rivm.nl/richtlijnen/influenza>. Accessed at 2 Jan 2019.
8. Mossong J, Hens N, Jit M et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. *PLoS Med* 2008, 5(3):e74.
9. Vynnycky E, Pitman R, Siddiqui R, Gay N, Edmunds WJ. Estimating the impact of childhood influenza vaccination programmes in England and Wales. *Vaccine* 2008, 26(41):5321-5330.
10. Vynnycky E, Edmunds WJ. Analyses of the 1957 (Asian) influenza pandemic in the United Kingdom and the impact of school closures. *Epidemiol Infect* 2008, 136(2):166-179.
11. DiazGranados CA, Denis M, Plotkin S. Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: a systematic review with meta-analyses of controlled trials. *Vaccine* 2012, 31(1):49-57.
12. Yorke JA, Nathanson N, Pianigiani G, Martin J. Seasonality and the requirements for perpetuation and eradication of viruses in populations. *Am J Epidemiol* 1979, 109(2):103-123.

13. May RM, Anderson RM. Population biology of infectious diseases: Part II. *Nature* 1979, 280(5722):455-461.
14. Pang T. *An Introduction to Computational Physics*. New York: Cambridge University Press; 1997.
15. Dolk FCK, De Boer PT, Nagy L et al. Consultations for influenza-like illness influenza-like illness in primary care in The Netherlands; a regression approach. Submitted.
16. Pitman R, Nagy L, Scott D. Cost-effectiveness of quadrivalent influenza vaccination in England and Wales. Cape Town, South Africa, poster P1-195; 2013.
17. Rivetti D, Jefferson T, Thomas R et al. Vaccines for preventing influenza in the elderly. *Cochrane Database Syst Rev* 2006(3):CD004876.
18. Chung JR, Flannery B, Ambrose CS et al. Live Attenuated and Inactivated Influenza Vaccine Effectiveness. *Pediatrics* 2019, 143(2).
19. Buchan SA, Booth S, Scott AN et al. Effectiveness of Live Attenuated vs Inactivated Influenza Vaccines in Children During the 2012-2013 Through 2015-2016 Influenza Seasons in Alberta, Canada: A Canadian Immunization Research Network (CIRN) Study. *JAMA Pediatr* 2018, 172(9):e181514.
20. Caspard H, Mallory RM, Yu J, Ambrose CS. Live-Attenuated Influenza Vaccine Effectiveness in Children From 2009 to 2015-2016: A Systematic Review and Meta-Analysis. *Open Forum Infect Dis* 2017, 4(3):ofx111.
21. Nagy L, Heikkinen T, Sackeyfio A, Pitman R. The Clinical Impact and Cost Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in Finland. *Pharmacoeconomics* 2016, 34(9):939-951.
22. Carrat F, Vergu E, Ferguson NM et al. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. *Am J Epidemiol* 2008, 167(7):775-785.
23. van den Wijngaard CC, van Asten L, Meijer A et al. Detection of excess influenza severity: associating respiratory hospitalization and mortality data with reports of influenza-like illness by primary care physicians. *Am J Public Health* 2010, 100(11):2248-2254.
24. van den Wijngaard CC, van Asten L, Koopmans MP et al. Comparing pandemic to seasonal influenza mortality: moderate impact overall but high mortality in young children. *PLoS One* 2012, 7(2):e31197.
25. Statistics Netherlands. Consumer prices; price index 2015=100 2017
<http://statline.cbs.nl/Statweb/publication/?DM=SLEN&PA=83131ENG&D1=0&D2=0&D3=64,77,90,103,116,129,142,155,168,181,194,207,220,233,246,259,272,285&LA=EN&HDR=T&STB=G1,G2&VW=T>.
 Accessed at Dec 1 2017.

26. Enserink R, Lugner A, Suijkerbuijk A, Bruijning-Verhagen P, Smit HA, van Pelt W. Gastrointestinal and respiratory illness in children that do and do not attend child day care centers: a cost-of-illness study. *PLoS One* 2014, 9(8):e104940.
27. Mangen MJ, Rozenbaum MH, Huijts SM et al. Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands. *Eur Respir J* 2015, 46(5):1407-1416.
28. Rozenbaum MH, Mangen MJ, Huijts SM, van der Werf TS, Postma MJ. Incidence, direct costs and duration of hospitalization of patients hospitalized with community acquired pneumonia: A nationwide retrospective claims database analysis. *Vaccine* 2015, 33(28):3193-3199.
29. National Health Care Institute. Guideline for economic evaluations in healthcare 2016 <https://english.zorginstituutnederland.nl/publications/reports/2016/06/16/guideline-for-economic-evaluations-in-healthcare>. Accessed at Dec 1 2017.
30. van Baal PH, Wong A, Slobbe LC, Polder JJ, Brouwer WB, de Wit GA. Standardizing the inclusion of indirect medical costs in economic evaluations. *Pharmacoeconomics* 2011, 29(3):175-187.
31. Bilcke J, Coenen S, Beutels P. Influenza-like-illness and clinically diagnosed flu: disease burden, costs and quality of life for patients seeking ambulatory care or no professional care at all. *PLoS One* 2014, 9(7):e102634.
32. National Health Care Institute. Medicijnkosten.nl 2018 www.medicijnkosten.nl. Accessed at 1 Aug 2018.
33. National Health Care Institute. Farmacotherapeutisch Kompas 2017 <https://www.farmacotherapeutischkompas.nl/>. Accessed at 1 December 2017.
34. van Werkhoven CH, Postma DF, Mangen MJ, Oosterheert JJ, Bonten MJ, group C-Ss. Cost-effectiveness of antibiotic treatment strategies for community-acquired pneumonia: results from a cluster randomized cross-over trial. *BMC Infect Dis* 2017, 17(1):52.
35. Friesema IH, Koppeschaar CE, Donker GA et al. Internet-based monitoring of influenza-like illness in the general population: experience of five influenza seasons in The Netherlands. *Vaccine* 2009, 27(45):6353-6357.
36. Statistics Netherlands. Labour participation; Key figures 2016 <http://statline.cbs.nl/Statweb/publication/?DM=SLNL&PA=82309NED&D1=22-23&D2=a&D3=18-22&D4=0&D5=69&HDR=G1,T&STB=G2,G3,G4&VW=T>. Accessed at 1 Dec 2017.
37. Statistics Netherlands. Working population; working time [In Dutch] 2017 <https://statline.cbs.nl/Statweb/publication/?DM=SLNL&PA=82647ned&D1=a&D2=0&D3=1-8&D4=74&HDR=G3&STB=G1,G2,T&P=T&VW=T>. Accessed at 1 Feb 2019.

38. Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. *J Health Econ* 1995, 14(2):171-189.
39. Miedema CJ, Kors AW, Tjon ATWE, Kimpen JL. Medical consumption and socioeconomic effects of infection with respiratory syncytial virus in The Netherlands. *Pediatr Infect Dis J* 2001, 20(2):160-163.
40. Statistics Netherlands. Projected Demographic Development, 2015-2060 [In Dutch] 2014 <https://statline.cbs.nl/Statweb/publication/?DM=SLNL&PA=83224NED&D1=a&D2=0,5,10,15,20,25,30,35,40,l&VW=T>. Accessed at 1 Jul 2016.
41. Mangen MJ, Bonten MJ, de Wit GA. Rationale and design of the costs, health status and outcomes in community-acquired pneumonia (CHO-CAP) study in elderly persons hospitalized with CAP. *BMC Infect Dis* 2013, 13:597.
42. Versteegh MM, Vermeulen KM, Evers SMAA, de Wit GA, Prenger R, Stolk EA. Dutch Tariff for the Five-Level Version of EQ-5D. *Value Health* 2016, 19(4):343-352.
43. Stichting Nationaal Programma Grieppreventie (SNPG). News letter SNPG November 2017 for health-care organizations (In Dutch) 2017 <https://www.snpg.nl/2017/11/23/nieuwsbrief-snpg-november-2017-zorgorganisaties/>. Accessed at 1 Aug 2018.
44. Centers for Disease Control and Prevention (CDC). CDC Vaccine Price List 2019 <https://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/index.html>. Accessed at 21 Jan 2019.
45. Organisation for Economic Co-operation and Development (OECD). Purchasing power parities (PPP) 2018 <https://data.oecd.org/conversion/purchasing-power-parities-ppp.htm>. Accessed at 1 Feb 2019.
46. Lugner AK, Mylius SD, Wallinga J. Dynamic versus static models in cost-effectiveness analyses of anti-viral drug therapy to mitigate an influenza pandemic. *Health Econ* 2010, 19(5):518-531.